Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed Feb 14, 2018 · 10-Q · 45 days after period end · 0001571049-18-000094
| Metric | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|
| Revenue | $771.89K | $303.14K | $994.89K |
| Net Income | -$1.92M | -$19.10M | -$16.86M |
| EPS Diluted | -$0.71 | -$0.82 | -$1.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Dec 31, 2017 · filed Feb 14, 2018 · 45 d after period end
